Dwarakanath Vuppalapati, MD
Psychiatry · Carson City, NVNPI 1063512804
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 27.1% of the total. Reporting peaked in 2022 at $569 and has fallen 51.2% since, to $278 in 2024.
Across 162 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$700
- Otsuka America Pharmaceutical, Inc.$370
- Lundbeck LLC$337
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$285
- Indivior Inc.$197
- Johnson & Johnson$194
- plus $503 from 7 others
What the payments were for
- Food & beverage$2,55999%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 40 | $700 |
| Otsuka America Pharmaceutical, Inc. | 26 | $370 |
| Lundbeck LLC | 22 | $337 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $285 |
| Indivior Inc. | 19 | $197 |
| Johnson & Johnson | 10 | $194 |
| Alkermes, Inc. | 7 | $131 |
| Teva Pharmaceuticals USA, Inc. | 6 | $112 |
| Vanda Pharmaceuticals Inc. | 5 | $76 |
| Neurocrine Biosciences, Inc. | 5 | $76 |
| Sunovion Pharmaceuticals Inc. | 3 | $54 |
| Eisai Inc. | 2 | $28 |
| Bioxcel Therapeutics, Inc. | 1 | $25 |
How this compares
$2,587 in reported general payments places this provider in the 75th percentile of 243 psychiatry providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 31 | $6,660 |
| Divalproex Sodium | 43 | $2,843 |
| Quetiapine Fumarate | 98 | $2,406 |
| Paliperidone ErPaliperidone | 11 | $1,380 |
| Carbamazepine | 29 | $1,376 |
| Divalproex Sodium ErDivalproex Sodium | 13 | $1,344 |
| Ziprasidone Hcl | 17 | $1,296 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $1,060 |
| Acamprosate Calcium | 11 | $1,047 |
| Duloxetine Hcl | 46 | $944 |
| Gabapentin | 54 | $908 |
| Olanzapine | 37 | $760 |
| Doxepin Hcl | 37 | $667 |
| Omeprazole | 24 | $658 |
| Trazodone Hcl | 75 | $619 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Carson City
- Kahmien LaruschCarson City$11K
- Jelena KunovacLas Vegas$1.2M
- John AnooshianLas Vegas$836K
- Sam ZandLas Vegas$410K
- Aaron RitterLas Vegas$173K
- Mustafa RawafLas Vegas$166K
- Philip MalinasReno$111K
- Dylan WintLas Vegas$86K
- Mujeeb ShadLas Vegas$55K
- Dax WolfordLas Vegas$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.